Leukemia & Lymphoma最新文献_第5页

Expanding access to leukemia specialists in the venetoclax era. 在venetoclax时代扩大白血病专家的机会。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-09-13 DOI: 10.1080/10428194.2026.2731270

Michael Daunov

引用次数: 0

Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities. 使用pemigatinib成功治疗嗜酸性粒细胞增多伴FGFR1重排和罕见染色体异常的髓系/淋巴肿瘤。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-23 DOI: 10.1080/10428194.2026.2721772

Masaya Abe, Fumiaki Konishi, Yuki Nakagawa, Kyotaro Ohno, Kumiko Yoshikawa, Nobuhiro Shimizu, Yasuharu Sato, Ichiro Takata, Toru Ueki, Hiroyuki Sugiura

引用次数: 0

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group. 维妥乐联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病的疗效和耐受性——波兰成人白血病研究组的现实世界分析。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-10 DOI: 10.1080/10428194.2026.2690480

Anita Soboń, Elżbieta Iskierka-Jażdżewska, Joanna Drozd-Sokolowska, Anna Puła, Małgorzata Gajewska, Michał Danecki, Łukasz Bołkun, Agata Ogłoza-Puchowska, Marta Morawska, Janusz Halka, Edyta Subocz, Agnieszka Podgórska, Jagoda Tryc-Szponder, Ewa Paszkiewicz-Kozik, Leszek Czernik, Anna Kopinska, Justyna Rybka, Agnieszka Szymczyk, Kamil Wdowiak, Paweł Steckiewicz, Aleksandra Gołos, Iwona Hus, Krzysztof Jamroziak, Tadeusz Robak, Ewa Lech-Maranda, Bartosz Puła

{"title":"Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.","authors":"Anita Soboń, Elżbieta Iskierka-Jażdżewska, Joanna Drozd-Sokolowska, Anna Puła, Małgorzata Gajewska, Michał Danecki, Łukasz Bołkun, Agata Ogłoza-Puchowska, Marta Morawska, Janusz Halka, Edyta Subocz, Agnieszka Podgórska, Jagoda Tryc-Szponder, Ewa Paszkiewicz-Kozik, Leszek Czernik, Anna Kopinska, Justyna Rybka, Agnieszka Szymczyk, Kamil Wdowiak, Paweł Steckiewicz, Aleksandra Gołos, Iwona Hus, Krzysztof Jamroziak, Tadeusz Robak, Ewa Lech-Maranda, Bartosz Puła","doi":"10.1080/10428194.2026.2690480","DOIUrl":"10.1080/10428194.2026.2690480","url":null,"abstract":"We collected clinical data on 363 patients with relapsed/refractory chronic lymphocytic leukemia (RR-CLL) treated with venetoclax-rituximab (VR) in a real-world setting. The median age was 69.5 years (range, 32.5-91.6 years), and the median number of prior lines of therapy was 2 (range, 1-10). Fifty-three recipients (53/362, 13.8%) had previously received BTKi. The median follow-up was 22.8 months. The overall response rate was 97.1%. The median PFS and OS were not reached. The estimated 3 y-PFS rate was 62.1% (95% CI 54.9-70.2), and the 3 y-OS rate was 69.0% (95% CI 62.3-76.4). Eighty-five (23.5%) patients had completed their therapy, while 106 (29.4%) discontinued prematurely. Reasons for therapy discontinuation included mainly patients' death (n = 36, 34%) and cytopenias (n = 17,16.0%). Treatment outcomes with the VR regimen in a real-life setting were slightly worse than those reported in the MURANO trial, likely due to the inclusion of patients with advanced ECOG and prior BTKi treatment.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2225-2234"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case. 在免疫检查点抑制剂治疗期间复发的霍奇金淋巴瘤中的嗜酸性粒细胞增多综合征和疑似髓系瘤变：一个罕见的病例。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-30 DOI: 10.1080/10428194.2026.2725345

Rowan A E Ibrahim, Basant Atef Ahmed, Ahmed Reda Bahr, Mohammed ElShazly

{"title":"Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.","authors":"Rowan A E Ibrahim, Basant Atef Ahmed, Ahmed Reda Bahr, Mohammed ElShazly","doi":"10.1080/10428194.2026.2725345","DOIUrl":"10.1080/10428194.2026.2725345","url":null,"abstract":"Classic Hodgkin lymphoma (cHL) generally has favorable outcomes with frontline ABVD chemotherapy; however, 15-30% of advanced-stage patients experience relapse. While PD-1 inhibitors like pembrolizumab have shown promise in relapsed/refractory cHL, immune-related adverse events remain incompletely characterized. We report a 56-year-old male with stage IV nodular sclerosis cHL who relapsed after multiple treatment lines including ABVD, DHAP, brentuximab vedotin, and ICE. Following pembrolizumab plus GVD (gemcitabine, vinorelbine, liposomal doxorubicin), he achieved complete metabolic response. Subsequently, he developed marked leukocytosis (WBC: 63,000/μL) with profound eosinophilia (53,000/μL), meeting criteria for hypereosinophilic syndrome (HES). Molecular workup revealed FIP1L1-PDGFRA rearrangement in 2% of cells. The patient required hospitalization for dehydration, renal dysfunction, and anasarca, and was managed with corticosteroids after hydroxyurea intolerance. This case uniquely documents HES as a rare complication of pembrolizumab/GVD in multiply relapsed cHL, occurring after extensive prior therapy that may have contributed to its development. The molecular findings suggest potential therapeutic avenues. Clinicians should maintain vigilance for eosinophilia during PD-1 inhibitor therapy, as HES management may take precedence over ongoing immunotherapy.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2337-2341"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148860406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multidisciplinary approach to early identification of inborn errors of immunity in patients with lymphoproliferation. 多学科方法早期识别淋巴增生患者先天性免疫缺陷。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-28 DOI: 10.1080/10428194.2026.2704265

Laia Alsina, Verónica Celis Passini, Carmen Garrido Colino, Armando López Guillermo, Mariana Bastos-Oreiro, Olga Balagué Ponz, Francisco Díaz-Crespo, Isabel Gómez Fernández, Maria Elena Seoane-Reula

{"title":"Multidisciplinary approach to early identification of inborn errors of immunity in patients with lymphoproliferation.","authors":"Laia Alsina, Verónica Celis Passini, Carmen Garrido Colino, Armando López Guillermo, Mariana Bastos-Oreiro, Olga Balagué Ponz, Francisco Díaz-Crespo, Isabel Gómez Fernández, Maria Elena Seoane-Reula","doi":"10.1080/10428194.2026.2704265","DOIUrl":"10.1080/10428194.2026.2704265","url":null,"abstract":"Inborn errors of immunity (IEIs) comprise a broader spectrum of manifestations than primary immunodeficiencies (PID). They often present with immune dysregulation manifestations such as lymphoproliferation (LP), a common yet underrecognized hallmark of IEIs that encompasses disorders ranging from chronic benign lymphadenopathy to malignant lymphoid neoplasms. Given the difficulties in diagnosing these conditions, including their heterogeneous presentation, this narrative review aims to increase awareness of IEIs by highlighting LP as a key clinical indicator, particularly in hematology-oncology settings. We present clinical, histopathological, and radiological features-especially those related to LP-that should prompt suspicion of IEIs. Additionally, we advocate for a multidisciplinary approach, fostering effective communication among all potentially involved specialists (clinical immunologists, hematologists, oncologists, radiologists, geneticists, and pathologists) to facilitate accurate, timely disease recognition. Early genetic diagnosis in IEIs is crucial for implementing genetic counseling, targeted therapies, and follow-up protocols, ultimately affecting patient outcomes and quality of life.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2192-2205"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis. 吡托布替尼与第二代共价布鲁顿酪氨酸激酶抑制剂治疗BTKi初发和复发难治性慢性淋巴细胞白血病的间接比较：一项网络荟萃分析的结果

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-06-21 DOI: 10.1080/10428194.2026.2690478

Stefano Molica, Diana Giannarelli, David Allsup

{"title":"An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.","authors":"Stefano Molica, Diana Giannarelli, David Allsup","doi":"10.1080/10428194.2026.2690478","DOIUrl":"10.1080/10428194.2026.2690478","url":null,"abstract":"While pirtobrutinib is established in Bruton tyrosine kinase inhibitor (BTKi)-refractory disease, its role in BTKi-naïve relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) remains unclear because of the absence of direct comparative trials with second-generation covalent BTKis. We conducted a systematic literature review and Bayesian network meta-analysis of randomized controlled trials (ELEVATE-RR, ALPINE, BRUIN-CLL-314) linked by a common comparator (ibrutinib). Across 814 patients, pirtobrutinib demonstrated efficacy comparable to acalabrutinib and zanubrutinib, with no significant differences in progression-free survival (PFS) (vs acalabrutinib: HR 0.73, 95% CrI 0.44-1.20 vs zanubrutinib: HR 1.12, 95% CrI 0.67-1.89), overall survival (OS), or overall response rate (ORR). Subgroup analyses by genomic risk were inconclusive. Safety profiles were broadly similar; however, pirtobrutinib was associated with a lower risk of cardiovascular adverse events compared with zanubrutinib (OR 0.52, 95% CrI 0.31-0.88) and similar risk relative to acalabrutinib (OR 1.09, 95% CrI 0.62-1.92). In conclusion, pirtobrutinib demonstrated efficacy and tolerability comparable to those of second-generation covalent BTKis, with a potential cardiovascular safety advantage over zanubrutinib in patients with R/R BTKi-naive CLL. However, given the indirect nature of the comparison, the limited evidence base, and between-study heterogeneity, these findings should be considered exploratory.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2217-2224"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148295670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FLAG-Ida-venetoclax in acute myeloid leukemia: real-world efficacy and the impact of venetoclax duration on outcomes. FLAG-Ida-venetoclax治疗急性髓性白血病：实际疗效和venetoclax持续时间对结果的影响。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-15 DOI: 10.1080/10428194.2026.2700469

Kateryna Fedorov, Melanie Naranjo, Jayda Esplund, Sara Leidy, Sarah E Profitt, Callee M Brooks, Ashwin Kishtagari, Sanjay R Mohan, Tara Lin, Michael R Savona, Jesus D Gonzalez-Lugo, Somedeb Ball

引用次数: 0

Optimized dosing of momelotinib in myelofibrosis through quantitative medicine: a clinical commentary. 通过定量医学优化莫米洛替尼在骨髓纤维化中的剂量：临床评论。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-09-11 DOI: 10.1080/10428194.2026.2721768

Georgios Vlasakakis, Fernando Carreño, Meenakshi Srinivasan, Catherine E Ellis, Mahshid Azimi, Jasmine Sahni

引用次数: 0

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. 静脉注射MCL1抑制剂S64315在髓系恶性肿瘤患者中的一期临床试验。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-26 DOI: 10.1080/10428194.2026.2699287

Norbert Vey, Olga Salamero, Ashish Bajel, Pau Montesinos, Naval Daver, Thomas Prebet, Ollivier Legrand, Christian Récher, Aline Maillard, Agnès Hemon, Valerie de Burgat, Annette Ervin-Haynes, Alberto Broniscer, Andrew H Wei

{"title":"Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.","authors":"Norbert Vey, Olga Salamero, Ashish Bajel, Pau Montesinos, Naval Daver, Thomas Prebet, Ollivier Legrand, Christian Récher, Aline Maillard, Agnès Hemon, Valerie de Burgat, Annette Ervin-Haynes, Alberto Broniscer, Andrew H Wei","doi":"10.1080/10428194.2026.2699287","DOIUrl":"10.1080/10428194.2026.2699287","url":null,"abstract":"Preclinical data support myeloid cell leukemia 1 (MCL1) inhibition in the treatment of acute myeloid leukemia (AML). Patients with relapsed/refractory myelodysplastic syndrome (n = 1) or AML (n = 32) or older patients with untreated AML ineligible to receive intensive chemotherapy (n = 5) were treated in this phase 1 study of S64315, an MCL1 inhibitor (NCT02979366). Seven dose levels (50, 100, 200, 250, 300, 400, and 500 mg) were tested. The most common toxicities were nausea and vomiting, diarrhea, and increased transaminases and troponin levels. Seven patients experienced dose-limiting toxicities (DLTs), including increased cardiac biomarkers (n = 3), grade 3 increased transaminases with hyperbilirubinemia (n = 2), and decreased cardiac ejection (n = 1). Three DLTs occurred at the 500-mg dose, which was intolerable; a maximum tolerated dose was not determined since fewer than six patients were treated at doses between 100 and 400 mg. Exposure to S64315 increased in a dose-dependent manner between 50 and 500 mg. There were no objective responses to therapy.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2305-2312"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148592391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy. 新诊断的急性髓性白血病老年人不适合强化治疗的治疗不公平。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-12 DOI: 10.1080/10428194.2026.2691911

Alain Mina, Yanqing Xu, Tatyana A Kapustyan, Mazaher Dhalla, Cheng Chen, Rajesh Kamalakar, Chia-Wei Lin, Esprit Ma, Melissa Montez, Zheng Wu, Tracy Yee, Haiyan Sun, Andrew Rava, Sonia Kim, Scott F Huntington, Amer M Zeidan

{"title":"Treatment inequity among older adults with newly diagnosed acute myeloid leukemia ineligible for intensive therapy.","authors":"Alain Mina, Yanqing Xu, Tatyana A Kapustyan, Mazaher Dhalla, Cheng Chen, Rajesh Kamalakar, Chia-Wei Lin, Esprit Ma, Melissa Montez, Zheng Wu, Tracy Yee, Haiyan Sun, Andrew Rava, Sonia Kim, Scott F Huntington, Amer M Zeidan","doi":"10.1080/10428194.2026.2691911","DOIUrl":"10.1080/10428194.2026.2691911","url":null,"abstract":"For adults with newly diagnosed acute myeloid leukemia (AML) aged ≥ 75 years or considered unfit for intensive induction therapy, the combination of venetoclax (VEN) and hypomethylating agents (HMAs) has become the standard of care. However, real-world data on demographic disparities in treatment uptake among Medicare beneficiaries remain limited. We conducted a retrospective cohort analysis using Medicare fee-for-service claims to identify factors influencing the receipt of AML-directed therapy. The study included 12,154 patients with newly diagnosed AML who were either ≥ 75 years and/or unfit for intensive induction chemotherapy. Overall, 5,647 patients received treatment, while 6,507 remained untreated. Treatment utilization increased over time. Untreated patients were older than treated patients (81.2 vs 77.9 years). Females were more likely to be untreated than males. Patients diagnosed in 2019 or later were more likely to receive therapy, and among those, 67.3% received VEN-based therapy. No significant differences in treatment receipt were observed by race or geographic residence. These findings suggest that factors extending beyond disease biology, such as age and sex, influence AML treatment uptake in the Medicare population. Management of AML demands a conscious effort to ensure equitable access to treatment and fair representation in clinical trials.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2244-2252"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0